Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study

• Published in: PloS one 2023-07, Vol.18 (7), p.e0285349-e0285349
• Main Authors: Sorrell, Lexy, Leta, Valentina, Barnett, Anton, Stevens, Kara, King, Angela, Inches, Jemma, Kobylecki, Christopher, Walker, Richard, Chaudhuri, K Ray, Martin, Hannah, Rideout, Jane, Sneyd, J Robert, Campbell, Sarah, Carroll, Camille
• Format: Article
• Language: English
• Subjects: Aftercare; Age; Aged, 80 and over; Basal ganglia; Biology and Life Sciences; Cardiovascular disease; Central nervous system diseases; Comorbidity; Complications and side effects; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 vaccines; Data collection; Dementia; Dementia disorders; Diabetes; Diagnosis; Disorders; Drug dosages; Ethnicity; Female; Frailty; Health risks; Hospitals; Humans; Hypertension; Immunization; Infections; Male; Males; Medical records; Medical research; Medicine and Health Sciences; Medicine, Experimental; Mental disorders; Missing data; Mortality; Movement disorders; Nervous system diseases; Neurodegenerative diseases; Neurological diseases; Pandemics; Parkinson Disease - complications; Parkinson Disease - epidemiology; Parkinson's disease; Parkinsonian Disorders - complications; Parkinsonian Disorders - epidemiology; Patient Discharge; Patient outcomes; Patients; Regression analysis; Regression models; Retrospective Studies; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Statistical models; Statistical significance; United Kingdom; United Kingdom - epidemiology; Vaccination; Viral diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0285349

Parkinson's disease has been identified as a risk factor for severe Coronavirus disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other concomitant and known risk factors such as comorbidities, age, and frailty remains unclear. To investigate clinical profiles and outcomes of people with Parkinson's disease and atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in a multicentre UK-based study. A retrospective cohort study of Parkinson's disease patients with a positive SARS-CoV-2 test admitted to hospital between February 2020 and July 2021. An online survey was used to collect data from clinical care records, recording patient, Parkinson's disease and COVID-19 characteristics. Associations with time-to-mortality and severe outcomes were analysed using either the Cox proportional hazards model or logistic regression models, as appropriate. Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day all-cause mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge. This first, multicentre, UK-based study on people with Parkinson's disease or atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous findings on clinical profiles and outcomes in this population.